CVE-2026-11937: Security vulnerabilities have been found in IBM Verify Identity Access and IBM Security Verify Access
IBM Security Verify Access 10.0 through 10.0.9.2 and IBM Verify Identity Access 11.0 through 11.0.3 and IBM Verify Identity Access Container 11.0 through 11.0.3 and IBM Security Verify Access Container 10.0 through 10.0.9.2 Reverse Proxy in certain configurations is vulnerable to a denial of service attack.
Other sources
IBM Verify Identity Access Reverse Proxy in certain configurations is vulnerable to a denial of service attack.
— IBM
Affected Software
Remediation
Recommended actions to resolve this vulnerability, in priority order.
- Upgrade
Upgrade
IBM Security Verify Accessto a version that resolves this vulnerability.Fixed in 10.0.9.2 IF2 - Upgrade
Upgrade
IBM Verify Identity Accessto a version that resolves this vulnerability.Fixed in 11.0.3 IF1 - Upgrade
Upgrade
IBM Verify Identity Access Containerto a version that resolves this vulnerability.Fixed in 11.0.3 - Upgrade
Upgrade
IBM Security Verify Access Containerto a version that resolves this vulnerability.Fixed in 10.0.9.2 - Upgrade
Upgrade
IBM Verify Identity Access Reverse Proxyto a version that resolves this vulnerability.Fixed in 11.0.3
Event History
Frequently Asked Questions
What is the severity of CVE-2026-11937?
The severity of CVE-2026-11937 is classified as low, with a score of 3.1.
What systems are affected by CVE-2026-11937?
CVE-2026-11937 affects IBM Security Verify Access versions 10.0 through 10.0.9.2 and IBM Verify Identity Access versions 11.0 through 11.0.3.
How does CVE-2026-11937 impact system availability?
CVE-2026-11937 can lead to a denial of service under certain configurations of the affected software.
How do I fix CVE-2026-11937?
To fix CVE-2026-11937, update to the latest versions of IBM Security Verify Access or IBM Verify Identity Access as recommended in IBM's security advisories.
Is there a workaround for CVE-2026-11937?
Currently, IBM has not specified any workarounds for CVE-2026-11937, so applying updates is the primary recommendation.